Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 51, 2012, Pages

  Mazor, Ronit ^a,b   Vassall, Aaron N ^a,c   Eberle, Jaime A ^a,d   Beers, Richard ^a   Weldon, John E ^a   Venzon, David J ^a   Tsang, Kwong Y ^a   Benhar, Itai ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

Antidrug antibodies; Deimmunization; Immunogenicity; Protein engineering

Indexed keywords

ALANINE; HLA DRB1 ANTIGEN; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RECOMBINANT IMMUNOTOXIN PE 38; UNCLASSIFIED DRUG;

ALLELE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADP RIBOSE TRANSFERASES; ANTIBODIES; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EPITOPES, T-LYMPHOCYTE; EXOTOXINS; GENE DELETION; GENETIC VARIATION; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MOLECULAR CONFORMATION; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); PSEUDOMONAS EXOTOXIN;

EID: 84871392604     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218138109     Document Type: Article

References (42)

1. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 71(20):6300-6309.
2. Kreitman RJ, et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30(15):1822-1828.
3. Wayne AS, et al. (2011) A novel anti-CD22 immunotoxin, moxetumomab pasudotox: Phase I study in pediatric acute lymphoblastic leukemia. Blood 118:1317a.
4. Hassan R, et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13(17):5144-5149.
5. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15(16):5274-5279.
6. Wolbink GJ, Aarden LA, Dijkmans BA (2009) Dealing with immunogenicity of biologicals: Assessment and clinical relevance. Curr Opin Rheumatol 21(3):211-215.
7. Krieckaert CL, Bartelds GM, Wolbink GJ (2010) Therapy: Immunogenicity of biologic therapies-we need tolerance. Nat Rev Rheumatol 6(10):558-559.
8. Nagata S, Pastan I (2009) Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev 61(11):977-985.
9. van den Berg HA, Rand DA (2004) Foreignness as a matter of degree: The relative immunogenicity of peptide/MHC ligands. J Theor Biol 231(4):535-548.
10. Shankar G, Shores E, Wagner C, Mire-Sluis A (2006) Scienti fi c and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 24(6):274-280.
11. Onda M, et al. (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177(12):8822-8834.
12. Hansen JK, et al. (2010) A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother 33(3):297-304.
13. Liu W, et al. (2012) Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 109(29):11782-11787.
14. Parker DC (1993) T cell-dependent B cell activation. Annu Rev Immunol 11:331-360.
15. Parker DC (1993) The functions of antigen recognition in T cell-dependent B cell activation. Semin Immunol 5(6):413-420.
16. Harding FA, et al. (2005) A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 4(11):1791-1800.
17. Tangri S, et al. (2005) Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 174(6):3187-3196.
18. Cantor JR, et al. (2011) Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci USA 108(4):1272-1277.
19. De Groot AS, Knopp PM, Martin W (2005) De-immunization of therapeutic proteins by T-cell epitope modification. Dev Biol (Basel) 122:171-194.
20. Moise L, et al. (2012) Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clin Immunol 142(3):320-331.
21. Jones TD, et al. (2004) The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J Interferon Cytokine Res 24(9):560-572.
22. Warmerdam PA, et al. (2002) Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemost 87(4):666-673.
23. Oseroff C, et al. (2010) Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol 185(2):943-955.
24. Deenadayalan A, et al. (2010) Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Proteomics 9(3):538-549.
25. Khan N, et al. (2007) T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 178(7):4455-4465.
26. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39(Database issue):D913-D919.
27. Marsh SGE, Parham P, Barber LD (2000) The HLA Factsbook (Academic, San Diego).
28. Singh H, Raghava GP (2001) ProPred: Prediction of HLA-DR binding sites. Bioinformatics 17(12):1236-1237.
29. Weldon JE, et al. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113(16):3792-3800.
30. Harding FA (2008) MedImmune L US 2008/0193976.
31. Tassignon J, et al. (2005) Monitoring of cellular responses after vaccination against tetanus toxoid: Comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR. J Immunol Methods 305(2):188-198.
32. De Rosa SC, et al. (2004) Vaccination in humans generates broad T cell cytokine responses. J Immunol 173(9):5372-5380.
33. Southwood S, et al. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160(7):3363-3373.
34. Allured VS, Collier RJ, Carroll SF, McKay DB (1986) Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA 83(5):1320-1324.
35. Liu Z, Williams KP, Chang YH, Smith JA (1993) Immunodominance: A single amino acid substitution within an antigenic site alters intramolecular selection of T cell determinants. J Immunol 151(4):1852-1858.
36. Allen PM, et al. (1987) Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope. Nature 327(6124):713-715.
37. Johansen BH, Vartdal F, Eriksen JA, Thorsby E, Sollid LM (1996) Identification of a putative motif for binding of peptides to HLA-DQ2. Int Immunol 8(2):177-182.
38. Yeung VP, et al. (2004) Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 172(11):6658-6665.
39. Kuan CT, Pastan I (1996) Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. Proc Natl Acad Sci USA 93(3):974-978.
40. Horton RM, Cai ZL, Ho SN, Pease LR (1990) Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. Biotechniques 8(5):528-535.
41. Pastan I, Beers R, Bera TK (2004) Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 248:503-518.
42. Liu W, et al. (2012) A recombinant immunotoxin engineered for increased stability by adding a disulfi de bond has decreased immunogenicity. Protein Eng Des Sel 25(1):1-6.